Category
Blends & Stacks
Combination products and multi-peptide stacks.
GLOW
GHK-Cu + BPC-157 + TB-500 Peptide Blend
Three-peptide blend of GHK-Cu, BPC-157, and TB-500, marketed for skin and soft-tissue repair. No human trial has tested the combination. Each component sits in Tier 3 evidence.
KLOW
KLOW Stack — KPV + Larazotide + Original GHK-Cu Stack + Wolverine Stack Combination
Multi-peptide research-chemical stack combining KPV, Larazotide, GHK-Cu, BPC-157, and TB-500 for combined gut, skin, and tissue-healing claims. Stack composition is not standardized. No trial of the combination exists.
Trinity-X
Trinity-X Tri-Agonist Research Peptide (GLP-1 / GIP / Glucagon)
Vendor-branded 39-amino-acid synthetic tri-agonist marketed as a GLP-1 / GIP / glucagon receptor activator. Not the same molecule as FDA-investigational retatrutide. No human trials under this name.
Wolverine Stack
Wolverine Stack (BPC-157 + TB-500 combination protocol)
Off-label community stack combining BPC-157 (pentadecapeptide from gastric juice) and TB-500 (thymosin beta-4 fragment). Named for the X-Men character Wolverine's regenerative healing factor. Used in research-chemical communities for soft-tissue recovery. No FDA approval.
Peptide Stacks and Blends
PeptScope catalogs published research on peptide stacks and multi-peptide blends used in clinical trials, animal studies, and off-label protocols. A stack is two or more peptides administered together. A blend is a single formulation containing multiple peptides at fixed ratios.
Most documented stacks combine compounds with complementary mechanisms. CJC-1295 with ipamorelin pairs a GHRH analog with a ghrelin-receptor agonist and produces a larger GH pulse than either compound alone in published pharmacokinetic work. BPC-157 with TB-500 is the most common tissue-repair stack in user reports, though no human trial has tested the combination. Cagrilintide with semaglutide is in active Phase 3 development by Novo Nordisk as a fixed-ratio injectable for obesity.
Most multi-peptide protocols outside FDA-approved drugs sit on preclinical or anecdotal evidence. Mechanistic plausibility is not proof of additive effect. The literature on combined dosing is thin compared with single-compound data.
Each entry on PeptScope names the individual compounds, their regulatory status, and the published interaction data where it exists. We do not recommend protocols for personal use. Research Use Only applies to most stack components in the United States and the European Union. Several stack components, including all GH secretagogues, are listed on the World Anti-Doping Agency prohibited list.
Browse the catalog by compound or read the deep-dive on each peptide to understand what is established and what remains hypothetical.